TIDMAVCT
RNS Number : 3732Z
Avacta Group PLC
15 March 2012
Press release 15 March 2012
Avacta Group plc
("Avacta" or "the Group")
Notice of Interim Results
Avacta Group plc (AIM:AVCT), a leading healthcare technology, reagents and consumables company providing proprietary analytical and diagnostics solutions to the life sciences/healthcare sector, will be announcing its interim results for the six months ended 31 January 2012 , on Wednesday, 25 April 2012.
An analyst briefing given by Alastair Smith, Chief Executive Officer and Tim Sykes, Chief Financial Officer will be held at 09:30hrs on Wednesday, 25 April 2012 at Abchurch Communications, 125 Old Broad Street, London EC2N 1AR.
-Ends-
For further information please contact:
Avacta Group plc Tel: 0844 414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Panmure Gordon (UK) Limited. Tel: 020 7459 3600
Andrew Burnett/ Fred Walsh www.panmure.com
Charles Leigh-Pemberton/Grishma
Patel
Media Enquiries Tel: 0207 398 7714
Abchurch Communications www.abchurch-group.com
Sarah Hollins / Adam Michael /
Oliver Hibberd
oliver.hibberd@abchurch-group.com
Notes to Editors:
Avacta Group plc, a world leading, UK-based healthcare equipment and instrumentation business, provides innovative, high value proprietary technologies and services to the life sciences/healthcare sector through two operating divisions:
Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a $200bn revenues market by 2013 and the fastest growing part of the pharmaceutical industry. The Group's technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Group's lead analytical instrument, Optim, is distributed through Pall Corporation in the US and South East Asia, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.
Avacta Animal Health provides diagnostic products and services for the $1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information, through point-of-care diagnostics, reagents and testing kits and laboratory based testing. Avacta's AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta's world leading allergy testing brand Sensitest(R). Avacta is currently developing further assays for the AX-1 system to diagnose other diseases in companion animals. Longer-term this technology will be transferred into the human clinical diagnostics market.
Avacta joined AIM in August 2006 and is based in Wetherby, England.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORUSRBRUNAOAAR
